The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Evidence for selective benefit of sequential treatment with azanucleosides in patients with myelodysplastic syndromes (MDS).
Rami S. Komrokji
No relevant relationships to disclose
Susmitha Apuri
No relevant relationships to disclose
Najla Al Ali
No relevant relationships to disclose
Eric Padron
No relevant relationships to disclose
Javier Pinilla-Ibarz
No relevant relationships to disclose
Viet Ho
No relevant relationships to disclose
Alan F. List
No relevant relationships to disclose
Jeffrey E. Lancet
No relevant relationships to disclose